The natural Nox2 inhibitor, celastrol, was found to effectively alleviate CAVD by inhibiting Nox2-mediated glycogen synthase kinase 3 beta/β-catenin pathway in aortic valvular interstitial cells (AVICs), and was also found to reduce ROS production, fibrosis, and severity of aortic stenosis in a rabbit CAVD model (Liu et al. 2020). This evidence concerns the gene CYBB and congenital bilateral aplasia of vas deferens from CFTR mutation.